Tagrisso and Diffuse large b-cell lymphoma - a phase IV clinical study of FDA data

Summary:

We study 100,476 people who take Tagrisso (osimertinib mesylate) or have Diffuse large b-cell lymphoma. No report of Diffuse large b-cell lymphoma is found in people who take Tagrisso.

The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.

What is Tagrisso?

Tagrisso has active ingredients of osimertinib mesylate. eHealthMe is studying from 19,890 Tagrisso users. Check the latest studies of Tagrisso.

What is Diffuse Large B-cell Lymphoma?

Diffuse large b-cell lymphoma (cancer of b cells, a type of white blood cell) is found to be associated with 987 drugs and 1,413 conditions by eHealthMe. Check the latest studies of Diffuse large b-cell lymphoma.

On Jul, 24, 2026

No report is found.

Do you take Tagrisso and have Diffuse large b-cell lymphoma?

- Check whether Diffuse large b-cell lymphoma is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tagrisso:

Tagrisso (19,890 reports)

Browse all side effects of Tagrisso:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Diffuse large b-cell lymphoma:

Diffuse large b-cell lymphoma

Browse all the conditions that are associated with Diffuse large b-cell lymphoma:

Diffuse large b-cell lymphoma

How the study uses the data?

The study uses data from the FDA. It is based on osimertinib mesylate (the active ingredients of Tagrisso) and Tagrisso (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.